These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 11956415

  • 1. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW, Small EJ.
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [Abstract] [Full Text] [Related]

  • 2. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

  • 3. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS, Ryan CW, Jung LL.
    J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
    [Abstract] [Full Text] [Related]

  • 4. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [Abstract] [Full Text] [Related]

  • 5. [Bone loss in men under androgen-deprivation therapy for prostate cancer].
    Ishizaka K, Machida T, Yoshida K.
    Nihon Rinsho; 2005 Apr; 63(4):721-6. PubMed ID: 15828242
    [Abstract] [Full Text] [Related]

  • 6. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 7. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA.
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [Abstract] [Full Text] [Related]

  • 8. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR.
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [Abstract] [Full Text] [Related]

  • 9. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR.
    Cancer; 2003 Feb 01; 97(3 Suppl):789-95. PubMed ID: 12548577
    [Abstract] [Full Text] [Related]

  • 10. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT.
    J Urol; 2000 Jan 01; 163(1):181-6. PubMed ID: 10604342
    [Abstract] [Full Text] [Related]

  • 11. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 12. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec 01; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 13. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI.
    J Clin Oncol; 2008 Nov 20; 26(33):5465-76. PubMed ID: 18955443
    [Abstract] [Full Text] [Related]

  • 14. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J, Maricić A, Valencić M, Oguić R, Krpina K, Protić A, Ivancić A, Bobinac M, Fuckar D, Vojniković B.
    Coll Antropol; 2008 Oct 20; 32 Suppl 2():79-81. PubMed ID: 19138011
    [Abstract] [Full Text] [Related]

  • 15. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Oct 20; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 16. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.
    Int J Urol; 2007 Dec 20; 14(12):1071-5. PubMed ID: 18036042
    [Abstract] [Full Text] [Related]

  • 17. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
    Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L.
    J Urol; 2010 Sep 20; 184(3):918-23. PubMed ID: 20643458
    [Abstract] [Full Text] [Related]

  • 18. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS, Pitts WR.
    J Urol; 2003 Nov 20; 170(5):1703-8. PubMed ID: 14532759
    [Abstract] [Full Text] [Related]

  • 19. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, Patterson AL.
    Can J Urol; 2007 Jun 20; 14(3):3551-9. PubMed ID: 17594745
    [Abstract] [Full Text] [Related]

  • 20. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS.
    Urol Clin North Am; 2004 May 20; 31(2):331-52. PubMed ID: 15123412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.